EC
IDYA icon

EntryPoint Capital’s IDEAYA Biosciences IDYA Stock Holding History

EntryPoint Capital’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,670
Closed -$377K – 793
2024
Q4 		$377K Buy
+14,670
New +$415K 0.16% 234
2024
Q3 		– Sell
-4,392
Closed -$154K – 855
2024
Q2 		$154K Buy
+4,392
New +$174K 0.23% 102

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

EntryPoint Capital's IDYA Position: Q1 2025 in Review

EntryPoint Capital sold out of IDEAYA Biosciences (IDYA) in Q1 2025, closing a stake of 14,670 shares — an estimated $377K sold.

EntryPoint Capital first reported a position in IDYA in Q2 2024 and held it in 2 quarters. The position peaked at $377K in Q4 2024. 207 funds tracked by Wall St. Rank hold IDYA as of Q1 2025.

  • EntryPoint Capital reported no remaining IDEAYA Biosciences position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 14,670 IDEAYA Biosciences shares in Q1 2025, an estimated $377K.
  • EntryPoint Capital first reported a position in IDEAYA Biosciences in Q2 2024 and held it in 2 quarters.
  • EntryPoint Capital's IDEAYA Biosciences position peaked at $377K in Q4 2024.
  • 207 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.